Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7829595 | AMGEN | Rapid dissolution formulation of a calcium receptor-active compound |
Sep, 2026
(3 years from now) | |
US9375405 | AMGEN | Rapid dissolution formulation of a calcium receptor-active compound |
Sep, 2026
(3 years from now) |
Market Authorisation Date: 08 March, 2004
Treatment: Method of treating hyperparathyroidism; Method of treating hypercalcemia
Dosage: TABLET;ORAL
11
United States
8
European Union
7
Spain
6
Denmark
6
Slovenia
6
Portugal
6
Poland
5
Hungary
4
Turkey
3
Japan
2
Brazil
2
Cyprus
1
Israel
1
South Africa
1
Mexico
1
Australia
1
Norway
1
Germany
1
Singapore
1
Argentina
1
Croatia
1
Malaysia
1
Korea, Republic of
1
Iceland
1
Taiwan, Province of China
1
China
1
EA
1
Canada
1
New Zealand
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic